Lifeward (LFWD) Panoramica del titolo
Lifeward Ltd., un'azienda di dispositivi medici, progetta, sviluppa e commercializza tecnologie che consentono la mobilità e il benessere nella riabilitazione e nella vita quotidiana di persone affette da patologie fisiche e neurologiche negli Stati Uniti, in Europa, in Germania, nell'Asia-Pacifico e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
LFWD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Lifeward Ltd.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$7.07 |
| Massimo di 52 settimane | US$14.88 |
| Minimo di 52 settimane | US$4.14 |
| Beta | 0.37 |
| Variazione di 1 mese | 10.47% |
| Variazione a 3 mesi | 6.48% |
| Variazione di 1 anno | -50.90% |
| Variazione a 3 anni | -85.87% |
| Variazione a 5 anni | -95.45% |
| Variazione dall'IPO | -99.90% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.Aggiornamento della narrazione • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.Recent updates
Aggiornamento della narrazione • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.Aggiornamento della narrazione • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
Aggiornamento della narrazione • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
Aggiornamento della narrazione • Apr 15
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.Aggiornamento della narrazione • Mar 31
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.Aggiornamento della narrazione • Mar 17
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).Aggiornamento della narrazione • Mar 03
LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.Aggiornamento della narrazione • Feb 17
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).Aggiornamento della narrazione • Feb 03
LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).Aggiornamento della narrazione • Jan 20
LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).Aggiornamento della narrazione • Jan 06
LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.Aggiornamento della narrazione • Dec 17
LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.Aggiornamento della narrazione • Dec 03
LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.Aggiornamento della narrazione • Nov 19
LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.Articolo di analisi • Sep 25
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...Aggiornamento della narrazione • Aug 16
FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.Articolo di analisi • Jun 19
Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...Nuova narrazione • May 11
AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.Articolo di analisi • Feb 05
Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...Articolo di analisi • Oct 30
Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...Articolo di analisi • Oct 15
Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Articolo di analisi • Aug 01
ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Articolo di analisi • May 30
Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Articolo di analisi • Mar 14
Investors Give ReWalk Robotics Ltd. (NASDAQ:LFWD) Shares A 28% Hiding
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shares have had a horrible month, losing 28% after a relatively good period...Rendimenti per gli azionisti
| LFWD | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | -2.9% | 6.1% | -3.3% |
| 1Y | -50.9% | -19.2% | 22.3% |
Ritorno vs Industria: LFWD ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -19.2 % nell'ultimo anno.
Rendimento vs Mercato: LFWD ha avuto una performance inferiore al mercato US che ha registrato un rendimento 22.3 % nell'ultimo anno.
Volatilità dei prezzi
| LFWD volatility | |
|---|---|
| LFWD Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: LFWD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di LFWD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2001 | 81 | William Grant | golifeward.com |
Lifeward Ltd., azienda produttrice di dispositivi medici, progetta, sviluppa e commercializza tecnologie che consentono la mobilità e il benessere nella riabilitazione e nella vita quotidiana di persone affette da patologie fisiche e neurologiche negli Stati Uniti, in Europa, Germania, Asia-Pacifico e a livello internazionale. L'azienda offre l'esoscheletro personale ReWalk e i dispositivi di esoscheletro per la riabilitazione di persone con lesioni al midollo spinale; ReStore Exo-Suit, un esoscheletro morbido destinato alla riabilitazione di persone con disabilità agli arti inferiori dovute a ictus; AlterG Anti-Gravity System per l'uso nella riabilitazione fisica e neurologica e nell'allenamento atletico; i dispositivi MyoCycle; e ReBoot, un esoscheletro morbido personale per l'uso domestico e in comunità da parte di persone post-ictus. L'azienda commercializza e vende i suoi prodotti direttamente a istituzioni e privati, oltre che attraverso distributori terzi.
Lifeward Ltd. Riepilogo dei fondamenti
| LFWD statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$19.65m |
| Utili (TTM) | -US$25.87m |
| Ricavi(TTM) | US$20.92m |
1.0x
Rapporto P/S-0.8x
Rapporto P/ELFWD è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| LFWD Conto economico (TTM) | |
|---|---|
| Ricavi | US$20.92m |
| Costo del fatturato | US$13.28m |
| Profitto lordo | US$7.65m |
| Altre spese | US$33.52m |
| Utili | -US$25.87m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -9.19 |
| Margine lordo | 36.55% |
| Margine di profitto netto | -123.66% |
| Rapporto debito/patrimonio netto | 115.7% |
Come si è comportato LFWD nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/10 22:22 |
| Prezzo dell'azione a fine giornata | 2026/06/10 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Lifeward Ltd. è coperta da 7 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |